Adenosine Receptor Agonist Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Adenosine Receptor Agonist
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indies Pharma | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 218054-001 | Aug 22, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Baxter Hlthcare Corp | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 217455-001 | May 23, 2023 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Dr Reddys | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 213210-001 | Apr 11, 2022 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Eugia Pharma | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 216437-001 | Oct 26, 2022 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Apotex | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 207604-001 | Apr 11, 2022 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Mylan | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 213856-001 | Apr 4, 2023 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
